Jaimie Rueter, Ph.D.

SFBN Feed: The top biopharma conferences in 2025 https://lnkd.in/gEPTCKNK With rare exceptions, biotechnology and pharmaceutical companies validate their business plans through clinical trials, results from which are often presented and dissected at medical conferences throughout the year. These are the forums where executives get [...] #BayArea #SanFrancisco #Biotech #Lifescience #News

1

As we approach the 15th Annual @World ADC meeting in San Diego, we are excited to explore potential partnerships and collaborations in the cutting-edge field of Antibody Drug Conjugates (ADCs) for oncology. ADCs are transforming cancer treatment by precisely targeting cancer cells, administering potent therapies directly where they are needed, while protecting healthy tissue in the process. We are particularly looking forward to Scientific Officer Lynn Kamen’s presentation titled, "Bioanalytical Strategies for Antibody Drug Conjugate Development," scheduled for November 5th from 6:30-7:30 PM. In her talk, Dr. Kamen will delve into vital bioanalytical strategies for assessing ADC pharmacokinetics and immunogenicity, emphasizing the significance of both molecular components for ensuring efficacy and safety. Join us in connecting with researchers and industry leaders as we work towards advancing oncology treatments. We can't wait to see you at booth 518 in San Diego! https://bit.ly/4dTJZVa #WorldADC #ADC #PharmaInnovation #Biotech #DrugDevelopment #BioAgilytix #AntibodyDrugConjugates #InnovationInBiotech

43

Latest on MDMA rejection; Novo vs. Lilly earnings; Recursion, Exscientia to merge; Q&A with Genentech CEO; and more https://lnkd.in/gRuf3XRp Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up [...] #LosAngeles #OrangeCountyCA #Biotech #Lifescience #News

1

#ICYMI: Last month we announced that we raised $132.5 million in an oversubscribed #SeriesC financing to advance our pipeline of potential therapies for fibrotic lung diseases and oncology. We are thankful for the support of our investors, board, #biotech community and the entire Endeavor BioMedicines team.     In this BioSpace article, get more details about what this financing means for the future of our pipeline and our goal to restore hope for patients with life-threatening diseases: https://bit.ly/4aVqAmo    #biotechnews #fundraising #venturecapital #oncology #lungdiseases

51

We would like to express our gratitude for one of founding sponsors, Armata Pharmaceuticals, Inc.🔬🧪👏 Your generous support made the Los Angeles chapter of WIB a reality 💙 Armata Pharmaceuticals, Inc.'s mission is one of the hot topics of the 21st century: antibiotic resistance. Through the use of phage therapeutics, Armata’s developments target the most resistant bacteria. Interested in joining Women In Bio? You can learn more about WIB membership and gain access to our video library, mentorship opportunities, and more here: https://lnkd.in/gkWMuhdp #BiotechLA #HealthTechLA #WomenInSTEM #Networking #WomenInLifeSciences #WomenInBiotech #WomenInPharma #WomenInResearch #WomenInBio #WomenInBioLosAngeles #WIB #WIBLA

33

1 Comment

Denovo Biopharma LLC received an $11.8 million grant from California Institute for Regenerative Medicine (CIRM) to advance its brain cancer therapy, DB107. The grant was awarded to conduct a Phase 1/2 clinical trial at the University of California, San Francisco (UCSF) for patients with high-grade glioma and glioblastoma. Their DB107 drug, acquired from Tocagen in 2020, uses gene therapy to selectively target and destroy tumor cells. They also claim to have developed a technology to identify biomarkers that predict a patient's response to their drugs. With plans to expand its drug development process and biomarker discovery initiative over the next five years, they have raised about $180 million since its launch in 2012. They have eight drugs in its pipeline targeting cancer and mental health disorders. For more on their cutting-edge research, subscribe to sdbj.com. https://lnkd.in/gU7HkSGu

4

🚨 Registration Open: Don’t Miss This Exclusive Roundtable Discussion at the Advanced Therapies Xchange – San Diego 2025! 🚨 📅 Date: February 25, 2025 ⏰ Time: 09:05 - 10:05 📍 Track: Cell & Gene (C&G) Manufacturing Are you grappling with the challenges of ensuring safety, purity, and potency in cell therapy manufacturing? Join us for an in-depth discussion led by Suman Kalyan Pradhan, Ph.D., Director of Analytical Development at Turnstone Biologics, as we explore innovative strategies to elevate manufacturing standards in cell therapy. 🔑 Key Discussion Points: ✅ Building an effective potency assurance strategy to ensure product consistency and efficacy ✅ Essential steps for comprehensive drug product characterization to evaluate safety, purity, and potency ✅ Linking Critical Process Parameters (CPPs) to Critical Quality Attributes (CQAs) for a robust manufacturing process 👨‍🔬 About the Expert: Dr. Suman K. Pradhan brings over a decade of experience in the cell therapy field, specializing in analytical tools, technologies, and CMC strategies for CAR-T and TIL therapies. With a PhD in Biophysics and postdoctoral research at UCSD and UCLA, Dr. Pradhan’s career spans leading organizations like Allogene Therapeutics and Atara Biotherapeutics. At Turnstone Biologics, he is driving innovation in TIL therapies for solid tumors. 💡 Why Attend? This session is your opportunity to gain actionable insights into cutting-edge analytical development practices and quality control measures for CGT manufacturing. 🎟️ Seats are limited! Secure your spot now for $150: https://lnkd.in/eCb4dQ_A Let’s advance the future of cell and gene therapy together. Don’t miss this chance to collaborate, learn, and innovate with industry leaders. 💊 Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. 💊 #CellTherapy #GeneTherapy #AdvancedTherapies #ManufacturingExcellence #CGTInnovation #Biotechnology #CellTherapy #GeneTherapy #AdvancedTherapies #ManufacturingExcellence #CGTInnovation #Biotechnology #AnalyticalDevelopment #QualityControl #PotencyAssurance #DrugCharacterization #CAR_T #TILTherapies #SolidTumors #Biopharma #Pharmaceuticals #LifeSciences #CellAndGeneTherapy #InnovativeManufacturing #ProcessDevelopment #TherapeuticInnovation #BioManufacturing #CGTLeadership #PharmaInnovation #NetworkingOpportunities #Collaboration #hubXchange #Xchanges #Roundtable #RegisterNow

7

Tomorrow, October 2nd, G&L experts will sit on the 'Maximize Your Drug Asset Value & Commercial Success' panel at Biocom California's offices in San Diego. Dr. Steven Hildemann, MD, PhD, R&D Physician at G&L, will be joined by industry experts including Krishna Allamneni, Executive Vice President, Chief Development Officer at Concarlo Therapeutics, Inc., and @Dr. Michael J. Nowak, Managing Partner, Nowak Ventures, LLC. With a focus on integrating regulatory, clinical, and commercial expertise, this discussion will help you develop novel strategies that set your asset apart. If you're in discovery, pre-clinical, or mid-phase clinical development, this is a must-attend event for gaining insights on increasing valuation at key inflection points. ***Please note, this event is now taking place at Biocom California's offices in San Diego - 10996 Torreyana Rd, San Diego, California 92121*** #HealthcareAdvisors #RegulatoryAffairs #QualityAssurance #ThoughtLeadership #Biopharma

25

Great news that Gilead’s PURPOSE 1 trial has demonstrated 100% efficacy of Lenacapavir, a twice-yearly injectable, in preventing new HIV infections among cisgender women and adolescent girls. These results are especially significant given adolescent girls and young women are particularly vulnerable to HIV. Gilead expects results in late 2024/early 2025 from the program’s other pivotal trial which is assessing twice-yearly Lenacapavir for PrEP among cisgender men who have sex with men, transgender men, transgender women and gender non-binary individuals who have sex with partners assigned male at birth in Argentina, Brazil, Mexico, Peru, South Africa, Thailand and the United States - groups who are underrepresented in HIV prevention trials and are disproportionately affected by the HIV epidemic. https://lnkd.in/e7s-d6f4

6

1 Comment

🌟 We're thrilled to spotlight our prestigious Pantheon Biopharma Award, honoring innovation and excellence in the biopharmaceutical industry. Presented to a biotech or pharmaceutical company that has made groundbreaking advancement and contribution to the California life sciences sector in the prior year. 🧬 Award Criteria: Our rigorous selection process evaluates key factors such as product launch, scientific breakthrough, facility openings, employee growth, or partnering deals/acquisitions that will foster future advancements for the industry. 🏆 Past Winners: Previous awardees have made significant contributions to biopharma development, demonstrating leadership and transformative impact in the field. Past distinguished winners include: BioMarin Pharmaceutical Inc. (2023) and Coherus BioSciences (2022). 🔗 Learn more about the award and our methodology: https://bit.ly/4fjq1Fx Join us in celebrating those who push the boundaries of science and healthcare! #Biopharma #Innovation #CaliforniaLifeSciences #Pantheon

14

We invite all San Diego Biotech Professionals to connect, share ideas, and discuss lab automation, data management and innovation strategies. Hear from Sandor Szalma, former Global Head of Genetics and Systems Biology at Takeda, about his informatics journey. Register Now: https://lnkd.in/guaef_pf #zifo #labdigitalization #digitaltransformation #pharmaceutical #labinformatics #laboperations #dataintegrity #FAIRdata #labautomation #scientificinformatics #drugdevelopment #datamanagement

31

We’re excited to attend the 19th Annual Peptide Therapeutics Symposium at Scripps Seaside Forum in La Jolla, CA, where industry leaders will come together for two days of cutting-edge discussions and networking. Don’t miss Ashli Simone, MS, Technical Market Manager at MOBILion Systems, as she presents her poster titled "Making Waves in GLP-1 Characterization: Solving Isomer Challenges with High-Resolution Ion Mobility." Discover how MOBIE is transforming peptide analysis, tackling the toughest challenges, and accelerating drug discovery pipelines. MOBILion's innovative separation science solutions are empowering researchers to unlock new possibilities in peptide therapeutics. We can’t wait to see you there! Learn more here: https://hubs.ly/Q02SX1lc0 #PeptideTherapeutics2024 #BiotechInnovation #AnalyticalChemistry #InnovationInAction #MOBILion #MassSpec #ProteinCharacterization #HRIMAdvancements #TeamMassSpec #bioanalytical #MassSpectrometry #SeparationSciences #SLIM #biopharma #biotherapeutics #Glycans #Isomerome #HRIM #molecules #peptides #oligos #antibodies #proteomics #metabolomics #Science #Research #MS #Bioinformatics #lipidomics #LCMS #HPL

11